For decades, multiple sclerosis was treated almost exclusively as an autoimmune disease of unknown origin. The emerging scientific consensus that Epstein-Barr virus is not merely correlated with MS but likely causally upstream of it fundamentally reframes what a cure might look like — shifting the target from the immune system's misfiring to the viral trigger itself.
This review, published in the Journal of Neuroimmunology, synthesizes the mechanistic case linking EBV to MS initiation and progression. The evidence is layered: EBV infection consistently precedes MS onset in longitudinal data, and the virus appears to drive pathology through at least three distinct pathways — molecular mimicry (where EBV antigens structurally resemble myelin proteins, provoking cross-reactive immune attacks), B cell immortalization (creating long-lived reservoirs of virus-harboring immune cells in the central nervous system), and periodic viral reactivation that may trigger clinical relapses. Crucially, the review notes that several existing MS disease-modifying therapies — particularly B cell-depleting agents like ocrelizumab and ofatumumab — may be suppressing EBV indirectly, offering a partial mechanistic explanation for their efficacy that goes beyond simple immune dampening.
The more consequential contribution here is the therapeutic roadmap the authors outline for directly targeting EBV in MS. CAR-T and CAR-NK cell therapies engineered to recognize EBV-infected B cells, adoptive T cell transfer using EBV-specific cytotoxic lymphocytes, "kick and kill" viral latency-disruption strategies, and prophylactic or therapeutic EBV vaccines all feature prominently. The mRNA-based EBV vaccine already in early-phase trials at Moderna lends immediate clinical relevance to this agenda. The limitation is that much of the mechanistic evidence remains correlational or derived from small experimental models; no randomized trial has yet proven that directly eliminating EBV load alters MS course. This review is nonetheless analytically significant — it positions MS as potentially the first common neurological disease with a modifiable viral etiology, which would be paradigm-shifting for prevention.